Nomegestrol Acetate/Estradiol

@article{Yang2012NomegestrolA,
  title={Nomegestrol Acetate/Estradiol},
  author={Lily P. H. Yang and Greg L. Plosker},
  journal={Drugs},
  year={2012},
  volume={72},
  pages={1917-1928}
}
Nomegestrol acetate/estradiol is a combined oral contraceptive with approval in many countries. This fixed-dose combination tablet contains nomegestrol acetate, a highly selective progestogen, and estradiol, a natural estrogen. It is the first monophasic combined oral contraceptive to contain estradiol, and is taken in 28-day cycles, consisting of 24 active therapy days with 4 placebo days (i.e. 24/4-day cycles).In two large, 1-year, randomized, open-label, multicentre, phase III trials in… Expand
View on Springer
ncbi.nlm.nih.gov
14 Citations
Highly Influential Citations
2
Background Citations
7
Methods Citations
1

14 Citations

Citation Type

Citation Type

Nomegestrol acetate/estradiol: a guide to its use in oral contraception
TLDR
Nomegestrol acetate/estradiol (Zoely™) is the first monophasic combined oral contraceptive to contain estradiol and was at least as effective (in terms of the Pearl Index) as drospirenone/ethinylESTradiol. Expand
The Effect of Therapeutic and Supratherapeutic Oral Doses of Nomegestrol Acetate (NOMAC)/17β-Estradiol (E2) on QTcF Intervals in Healthy Women: Results from a Randomized, Double-Blind, Placebo- and Positive-Controlled Trial
TLDR
This thorough QT/QTc study showed that therapeutic and supratherapeutic doses of NOMAC/E2 were not associated with clinically relevant QTc interval prolongation in healthy women after a 2-week period of dosing. Expand
Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea
TLDR
Both oral contraceptives reduced similarly primary dysmenorrhea, with E2/NOMAC also reducing withdrawal bleedings and being neutral on lipid metabolism. Expand
Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats
TLDR
NOMAC had a widespread distribution in tissues, including ovary, pituitary, and hypothalamus, which are main target tissues where NOMAC inhibits ovulation, and enteredohepatic circulation was found in the drug elimination. Expand
Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.
TLDR
The whole-body physiology-based model described here complements classic noncompartmental and population PK approaches and has the ability to expand to adolescent postmenarcheal adolescent population data and applying physiological scaling. Expand
An Improved Synthesis of Nomegestrol Acetate
Oral contraceptives (OCs) are synthetic steroids, or progestins, which are structurally related to testosterone or to progesterone. Many progestins have been synthesized and approved for OCs,… Expand
Isolation, synthesis, and cytotoxicity evaluation of two impurities in nomegestrol acetate
TLDR
Both impurities and NOMAc were evaluated for their in vitro cytotoxicities against L02 liver cells, mesenchymal stem cells, MCF‐7 breast cancer cells, and C33A cervical cancer cells and impurity B did not show significant cytotoxicity to any of the cell lines tested. Expand
Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report
TLDR
The use of Nomegestrol acetate as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC. Expand
Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients
TLDR
The first cases of meningiomas responsiveness to discontinuation of hormonal therapy with NOMAC are reported, similar to cases associated with long-term CPA intake, tumor reduction, and improvement of clinical symptoms can be observed after cessation of NOMac. Expand
Modeling the Photocatalytic Mineralization in Water of Commercial Formulation of Estrogens 17-β Estradiol (E2) and Nomegestrol Acetate in Contraceptive Pills in a Solar Powered Compound Parabolic Collector
TLDR
The optimum removal of the estrogens and TOC was achieved at a catalyst concentration of 0.4 g/L in 29 mm diameter tubular CPC reactors which approached the optimum catalyst concentration and optical thickness determined from the modeling of the absorption of solar radiation in the CPC, by the six-flux absorption-scattering model (SFM). Expand
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Estradiol Valerate/Dienogest
TLDR
Estradiol valerate/dienogest was generally well tolerated in this population of women, with the nature of adverse events generally similar across the studies and between estradiol valerian/dianogest and ethinylestradiol/levonorgestrel. Expand
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
TLDR
The NOMAC/E2 pill regimen has fewer adverse effects on blood biological coagulation and fibrinolysis markers than LNG/EE, and could have a more favourable venous thromboembolism risk profile than Lng/EE. Expand
Nomegestrol Acetate
This review summarizes the pharmacology, safety and clinical efficacy of nomegestrol acetate, based on the available published literature, and assesses the pharmacological characteristics that… Expand
Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: A double-blind, randomised, dose-finding pilot study
TLDR
The dose of 2.5 mg NOMAC was confirmed to be optimal to inhibit both ovulation and follicular maturation and a statistically significant inverse correlation was found between E2 plasma levels and NOMac dose. Expand
Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
TLDR
NOMAC/E2 achieves consistent ovulation inhibition, with suppressive effects on the ovaries at least similar to those of DRSP/EE. Expand
Effect of nomegestrol acetate, a new 19‐nor‐progesterone derivative, on pituitary‐ovarian function in women
TLDR
Results show an hypothalamic‐pituitary effect and suggest an ovarian action, both responsible for a potentially useful contraceptive property, in normally menstruating women treated with NOM Ac during the third consecutive cycle. Expand
Efficacy, Safety, and Tolerability of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate and 17&bgr;-Estradiol: A Randomized Controlled Trial
TLDR
Nomegestrol acetate and 17&bgr;-E2 were well tolerated and provided excellent contraceptive efficacy and acceptable cycle control and the most frequently reported adverse events were acne, weight gain, and irregular withdrawal bleeding. Expand
Review of clinical experience with estradiol in combined oral contraceptives.
TLDR
More recent studies employing endometrial-focused progestins, e.g., DNG, and multiphasic dosing regimens appear to be a promising approach for an E2-based COC that provides efficient ovulation inhibition and acceptable cycle control. Expand
Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen
  • D. Mansour, C. Verhoeven, +5 authors T. Korver
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2011
TLDR
Assessment of the efficacy, cycle control and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol shows NOMAC/E2 provides high contraceptive efficacy with acceptable cycle control as well as an overall adverse event profile similar to that of DRSP/EE. Expand
Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism
  • U. Ågren, Marjatta Anttilat, +4 authors E. Mommers
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2011
TLDR
The monophasic COC NOMAC/E2 had less influence on haemostasis, lipids and carbohydrate metabolism than the COC LNG/EE. Expand
...
1
2
3
4
...